부산대학교 도서관

Simple Summary: The SPOCK1 proteoglyan has been discovered as an oncogene with overexpression, promoting tumor formation and progression, and linked with poor survival rates. However, information on SPOCK1′s significance in ovarian cancer is limited. The purpose of this study was to explore the role of SPOCK1 in ovarian cancer. With that goal, two ovarian cancer cell lines, as well as tissue and serum samples from patients suffering from ovarian cancer, were studied. The proteoglycan was overproduced in cell lines upon the addition of artificial SPOCK1 vector. As a result, SPOCK1 overexpressing cells increased their rate of cell division and migration. In line with this, ovarian cancer tissues and blood samples exhibited higher SPOCK1 levels than healthy controls. Furthermore, SPOCK1 levels in untreated ovarian cancer serum and tissue samples were higher than in chemotherapy-treated patients. Our results indicate that SPOCK1 may serve as a therapeutic target and could be utilized for monitoring ovarian cancer. Purpose: Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan 1 (SPOCK1) has been found in a variety of malignant tumors and is associated with a poor prognosis. We aimed to explore the role of SPOCK1 in ovarian cancer. Methods: Ovarian cancer cell lines SKOV3 and SW626 were transfected with SPOCK1 overexpressing or empty vector using electroporation. Cells were studied by immunostaining and an automated Western blotting system. BrdU uptake and wound healing assays assessed cell proliferation and migration. SPOCK1 expression in human ovarian cancer tissues and in blood samples were studied by immunostaining and ELISA. Survival of patients with tumors exhibiting low and high SPOCK1 expression was analyzed using online tools. Results: Both transfected cell lines synthesized different SPOCK1 variants; SKOV3 cells also secreted the proteoglycan. SPOCK1 overexpression stimulated DNA synthesis and cell migration involving p21CIP1. Ovarian cancer patients had increased SPOCK1 serum levels compared to healthy controls. Tumor cells of tissues also displayed abundant SPOCK1. Moreover, SPOCK1 levels were higher in untreated ovarian cancer serum and tissue samples and lower in recipients of chemotherapy. According to in silico analyses, high SPOCK1 expression was correlated with shorter survival. Conclusion: Our findings suggest SPOCK1 may be a viable anti-tumor therapeutic target and could be used for monitoring ovarian cancer. [ABSTRACT FROM AUTHOR]